H.C. Wainwright Reiterates a Buy Rating on BELLUS Health (BLU)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on BELLUS Health (BLU) today and set a price target of $10.00. The company’s shares closed last Thursday at $2.45, close to its 52-week low of $2.01.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.3% and a 45.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Zentalis Pharmaceuticals, and KalVista Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BELLUS Health with a $9.00 average price target, which is a 261.4% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.03 and a one-year low of $2.01. Currently, BELLUS Health has an average volume of 953.9K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BLU in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.